While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.

Luckily for you, we built StockStory to help you separate the good from the bad. Keeping that in mind, here are three cash-producing companies that don’t make the cut and some better opportunities instead.

Genesco (GCO)

Trailing 12-Month Free Cash Flow Margin: 3.4%

Spanning a broad range of styles, brands, and prices, Genesco (NYSE: GCO) sells footwear, apparel, and accessories through multiple brands and banners.

Why Is GCO Risky?

1. Weak same-store sales trends over the past two years suggest there may be few opportunities in its core markets to open new locations
2. Waning returns on capital from an already weak starting point displays the inefficacy of management’s past and current investment decisions
3. 5× net-debt-to-EBITDA ratio makes lenders less willing to extend additional capital, potentially necessitating dilutive equity offerings

Genesco is trading at $30.99 per share, or 14x forward P/E. Read our free research report to see why you should think twice about including GCO in your portfolio.

MGP Ingredients (MGPI)

Trailing 12-Month Free Cash Flow Margin: 14.2%

Headquartered in Atchison, Kansas, MGP Ingredients (NASDAQ: MGPI) is a leading supplier of high-quality ingredients to the food and beverage industry

Why Do We Pass on MGPI?

1. Annual revenue declines of 11.8% over the last three years indicate problems with its market positioning
2. Operating profits fell over the last year as its sales dropped and it struggled to adjust its fixed costs
3. Earnings per share have dipped by 17% annually over the past three years, which is concerning because stock prices follow EPS over the long term

At $18.69 per share, MGP Ingredients trades at 12x forward P/E. Dive into our free research report to see why there are better opportunities than MGPI.

Thermo Fisher (TMO)

Trailing 12-Month Free Cash Flow Margin: 14.1%

With over 14,000 sales personnel and a portfolio spanning more than 2,500 technology manufacturers, Thermo Fisher Scientific (NYSE: TMO) provides scientific equipment, reagents, consumables, software, and laboratory services to pharmaceutical, biotech, academic, and healthcare customers worldwide.

Why Do We Think Twice About TMO?

1. Scale is a double-edged sword because it limits the company’s growth potential compared to its smaller competitors, as reflected in its below-average annual revenue increases of 2% for the last two years
2. Organic revenue growth fell short of our benchmarks over the past two years and implies it may need to improve its products, pricing, or go-to-market strategy
3. Costs have risen faster than its revenue over the last five years, causing its adjusted operating margin to decline by 8.3 percentage points

Thermo Fisher’s stock price of $501.82 implies a valuation ratio of 19.8x forward P/E. Check out our free in-depth research report to learn more about why TMO doesn’t pass our bar.

High-Quality Stocks for All Market Conditions

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it's flagging for this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.